PDC*lung01 is a therapeutic cancer vaccine based on an irradiated plasmacytoid dendritic cell line loaded with HLA-A*02:01-restricted peptides including NY-ESO-1, melanoma antigen gene (MAGE)-A3, MAGE-A4, multi-MAGE-A, mucin 1 (MUC1), survivin and Melan-A, which are tumor antigens associated with NSCLC (Figure 5) [53]. Here, HLA-A is linked to non-small cell lung carcinoma.